Login to Your Account

Clinic Roundup

Thursday, April 25, 2013
• Chimerix Inc., of Durham, N.C., said that its Phase III SUPPRESS trial of CMX001 for cytomegalovirus following allogeneic hematopoietic stem cell transplant now has a finalized design for population, endpoints, dosing and duration of therapy. The details were settled following an end-of-Phase II meeting with the FDA in May 2012.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription